Key facts
- AstraZeneca CEO Pascal Soriot discussed the impact of AI on drug development.
- Soriot stated AI is helping the company develop medicines faster.
- AI is also improving decision-making in the research process.
AstraZeneca CEO Pascal Soriot has commented on the transformative impact of artificial intelligence on the pharmaceutical industry. He indicated that AI is significantly enhancing the company's ability to develop new medicines at a faster pace. Furthermore, Soriot highlighted that AI is instrumental in making more informed and intelligent decisions across the entire research and development pipeline, ultimately boosting the probability of successful drug discovery and development.